Cite
HARVARD Citation
Hutmacher, M. et al. (2017). Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. CPT: pharmacometrics & systems pharmacology. pp. 322-330. [Online].